Good morning from the Financial Times. Today is Tuesday, April 20th, and this is your F-T news briefing.

Johnson & Johnson reports earnings today as a cloud hangs over its COVID-19 vaccine and its other vaccine programs.

And Apple is allowing a banned app back on its online store.

And the most powerful man in Cuba is no longer a Castro. How will he lead?

The lot of Cuban citizens felt tremendous personal loyalty to the Castro brothers, which is difficult to transfer to a post-revolutionary generation.

I'm Mark Filipino, and here's the news you need to start your day.

Johnson & Johnson announces earnings today as U.S. regulators continue to recommend that the company's single shot COVID-19 vaccine not be used.

Regulators are still investigating the risks after six women reported blood clots.

Now we should say this is out of nearly 7 million doses that have been administered so far.

It's unclear what regulators will do, but the scare could damage Johnson & Johnson's longer-term vaccine program.

Here's the F-T's U.S. Pharmaceuticals reporter, Niko Azgari.

So J&J is working on multiple different vaccines from Ebola to Zika virus to a respiratory virus that causes the can cause bronchitis.

And all of these vaccines use the same technology as its COVID vaccine. It's called adenovirus or adenovirus-based vaccine.

So if U.S. health agencies and the scientists all around the country that are working on figuring out what's causing the blood clots, determine that it's this type of technology and this type of vaccine that's behind it.

Then it could put people off getting the other vaccines that use the same technology.

And I understand that European regulators are looking into this blood clot issue too, right?

Yes, it's exactly the same issue. European regulators are looking into what's causing the very rare but can be very severe blood clots.

And today the European Medicines Agency will say what the outcome of its findings are.

Niko, could any of this actually affect earnings?

In short, no, not really, because J&J isn't selling its vaccine, its COVID vaccine for profit. So there will be no financial impact really from this.

Niko Azgari is the F-T's U.S. Pharmaceuticals reporter. Thank you, Niko.

Thank you.

...